Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

50.72 +0.97 (+1.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Legend Biotech Corp ADR

< Previous 1 2 3 4 Next >
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
From Legend Biotech Corporation
Via Business Wire
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Legend Biotech Corp. (NASDAQ: LEGN) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Legend Biotech Announces Appointment of Chief Medical Officer
From Legend Biotech
Via Business Wire
Legend Biotech Establishes Strategic Advisory Board
From Legend Biotech
Via Business Wire
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2)
From Legend Biotech
Via Business Wire
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI® (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
From Legend Biotech
Via Business Wire
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
From Legend Biotech
Via Business Wire
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
From Legend Biotech
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022
From Legend Biotech Corporation
Via Business Wire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
From Legend Biotech Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Participation in Upcoming Investor Conferences
From Legend Biotech
Via Business Wire
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
From Legend Biotech
Via Business Wire
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech Corporation
Via Business Wire
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
From Legend Biotech
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.